Jean-Michel Levy
Directeur/Membre du Conseil chez ILTOO Pharma SAS
Profil
Jean-Michel Levy is currently a Director at ILTOO Pharma SAS.
Previously, he worked as an Independent Director at Stallergenes SA from 2009 to 2012 and as a Non-Executive Director at Zentiva Group as.
Postes actifs de Jean-Michel Levy
| Sociétés | Poste | Début |
|---|---|---|
ILTOO Pharma SAS
 ILTOO Pharma SAS Miscellaneous Commercial ServicesCommercial Services ILTOO Pharma SAS is a French clinical-stage biotechnology company that focuses on developing therapies to re-educate the immune system and revolutionize the treatment of auto/neuro-immune diseases. The private company is based in Paris, France, and the CEO of the company is Jeff Lyons. The company's main focus is on amyotrophic lateral sclerosis (ALS) and systemic lupus erythematosus (SLE), which are progressive and life-threatening neuromuscular disorders affecting motor neurons in both the brain and spinal cord and a chronic systemic autoimmune disease that affects the joints, kidney, mucus membrane, and blood vessels, respectively. | Directeur/Membre du Conseil | - |
Anciens postes connus de Jean-Michel Levy
| Sociétés | Poste | Fin |
|---|---|---|
| STALLERGENES | Directeur/Membre du Conseil | 27/05/2012 |
Zentiva Group as
 Zentiva Group as Pharmaceuticals: MajorHealth Technology Zentiva Group as develops, manufactures and markets pharmaceuticals. Its products include generics for the treatment of cardiovascular, central nervous, and blood diseases, as well as anti-inflammatory drugs. The company was founded in 1933 and is headquartered in Prague, Czech Republic. | Directeur/Membre du Conseil | 02/04/2009 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Zentiva Group as
Zentiva Group as Pharmaceuticals: MajorHealth Technology Zentiva Group as develops, manufactures and markets pharmaceuticals. Its products include generics for the treatment of cardiovascular, central nervous, and blood diseases, as well as anti-inflammatory drugs. The company was founded in 1933 and is headquartered in Prague, Czech Republic. | Health Technology |
Stallergenes SA
 Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
ILTOO Pharma SAS
ILTOO Pharma SAS Miscellaneous Commercial ServicesCommercial Services ILTOO Pharma SAS is a French clinical-stage biotechnology company that focuses on developing therapies to re-educate the immune system and revolutionize the treatment of auto/neuro-immune diseases. The private company is based in Paris, France, and the CEO of the company is Jeff Lyons. The company's main focus is on amyotrophic lateral sclerosis (ALS) and systemic lupus erythematosus (SLE), which are progressive and life-threatening neuromuscular disorders affecting motor neurons in both the brain and spinal cord and a chronic systemic autoimmune disease that affects the joints, kidney, mucus membrane, and blood vessels, respectively. | Commercial Services |
